> Overview

The company’s products are antibodies and peptide-therapeutics designed to modulate the immune response allowing it to exert its anti-cancer activity in an effective manner.

Our lead product, pidilizumab (CT-011), is a humanized monoclonal antibody that exhibits efficient anti-cancer immune response against a wide variety of mouse and human tumor models. Pidilizumab is being developed as a treatment for hematological malignancies and solid tumors.